J&J agreed to buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of reentry into neuroscience by large ...

Cigna and Centene were among a dozen companies that appeared on the initial JPM agenda that have bowed out of the conference.

J&J said it would buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of large drugmakers’ reentry into ...

Duke neuroscientist Kafui Dzirasa wants nothing less than to reengineer the brain’s electrical patterns to treat anxiety, ...

This amounts to one of the most significant federal government investments in the behavioral health sector in history. For ...

Asian American populations, particularly when broken down into ethnic groups, have allergy health outcomes that are distinct ...

Eli Lilly said it would acquire a cancer program from Scorpion Therapeutics in a deal worth up to $2.5 billion, as it broadens its pipeline.

The changes reflect “a cultural shift” around obesity medications, said Diana Zuckerman, president of the nonprofit National ...

Enrollment of Black and Hispanic students in medical schools dropped precipitously last year after the Supreme Court banned ...

Basic public health protections help augment our national security protections,” particularly when it comes to emerging ...

The Biden administration’s final regulation affecting the Medicare Advantage industry would come with a much lighter touch ...

Many new names sounded as if they’d been cooked up by a medieval monk. HIV-1 would henceforth be known as Lentivirus ...